Mr. Neil Klompas - 05 Jul 2022 Form 4 Insider Report for Zymeworks Inc.

Reporting relationship: Chief Operating Officer
Issuer ticker: N/A
Reported as of: 05 Jul 2022
Net transaction value: +$6,878
SEC form: 4
Accepted by SEC: 05 Jul 2022, 21:00:10 UTC
Prior SEC filing: 11 Mar 2022
Next SEC filing: 06 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Daniel Dex, Attorney-in-Fact

Key filing fact

Mr. Neil Klompas filed Form 4 for Zymeworks Inc. on 05 Jul 2022.

Key facts

This page summarizes Mr. Neil Klompas's Form 4 filing for Zymeworks Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jul 2022, 21:00.

Change

Previous filing in this sequence was filed on 11 Mar 2022.
Current net transaction value: +$6,878.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZYME transaction

Common Shares

Award

Transaction value: $6,878
Shares: +1,525
Change %: +11%
Price: $4.51
Shares after: 14,801
Date: 05 Jul 2022
Ownership: Direct
Footnotes: F1

ZYME holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 700
Date: 05 Jul 2022
Ownership: Held by spouse

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period January 1, 2022 through June 30, 2022. In accordance with the ESPP, these shares were purchased at a price equal to 85% the closing price of the Issuer's common shares on June 30, 2022.